Key result
Recent trials lower statin thresholds in CAD, adding CRP alongside LDL-C as key targets.
Why the study?
Coronary artery disease is the largest cause of premature death and optimal therapeutic goals for statin therapy continue to evolve beyond traditional LDL cholesterol targets.
What are the optimal therapeutic goals for statin use in patients with coronary artery disease?
What are the optimal therapeutic goals for statin use in patients with coronary artery disease?
This review highlights the evolving, more aggressive therapeutic goals for statin therapy in coronary artery disease, including both LDL and CRP targets.
Answers are grounded in this paper and cite their sources.
May support CRP alongside LDL as statin targets in CAD; leaves open optimal goals pending prospective trials.
PURPOSE OF REVIEW: Coronary artery disease is the largest cause of premature death in the Western world. Lipid-lowering therapy with statins has revolutionized the management of this condition over the past decade. RECENT DEVELOPMENTS: Successive clinical trials have lowered the treatment bar for statin therapy in patients with coronary artery disease. In addition to traditional markers of efficacy such as low-density lipoprotein cholesterol, emerging targets such as C-reactive protein are becoming recognized as important therapeutic goals. SUMMARY: This review focuses on the important contributions to the literature during the past year and provides an expert opinion of the therapeutic goals for statin therapy.
No takes yet. Share an insight, caveat, or question.
Ray et al. (2005) conducted a review in Coronary artery disease. Statin therapy was evaluated. Recent clinical trials have lowered the treatment bar for statin therapy in coronary artery disease, with emerging targets like C-reactive protein becoming recognized alongside LDL cholesterol.
Synapse has enriched 10 related papers. Consider them for comparative context: